New liver drug safety trial aims to help hepatitis b patients
NCT ID NCT07343778
First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests whether high doses of hydronidone capsules are safe for people with liver scarring (fibrosis) or cirrhosis caused by chronic hepatitis B. About 300 adults will take the drug three times daily for 28 days and be monitored for side effects. The goal is to see if the drug can be tolerated without serious harm, not to cure the liver disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth People's Hospital of Zhengzhou City
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.